metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology O-9 PRESENCE OF METABOLIC ASSOCIATED LIVER DISEASE IN AUTOIMMUNE HEPATITIS IS AS...
Información de la revista
Vol. 29. Núm. S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(febrero 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(febrero 2024)
Acceso a texto completo
O-9 PRESENCE OF METABOLIC ASSOCIATED LIVER DISEASE IN AUTOIMMUNE HEPATITIS IS ASSOCIATED WITH ADVANCED LIVER FIBROSIS
Visitas
162
Giselle Arévalo1, Daniela Simian1, Jorge Chiong2, Consuelo Palomo1, Laura Carreño1, Jaime Poniachik1, Álvaro Urzúa1
1 Sección de Gastroenterología, Hospital Clínico Universidad de Chile, Santiago, Chile
2 Facultad de Medicina, Universidad de Chile, Santiago, Chile
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Descargar PDF
Estadísticas
Figuras (1)
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S1

Abstracts of the 2023 Annual Meeting of the ALEH

Más datos
Introduction and Objectives

Metabolic associated liver disease (MAFLD) is one of the most frequent causes of chronic liver disease worldwide. Steatohepatitis is a major risk factor for fibrosis and its progression. MAFLD might be present in other causes of chronic liver damage, such as autoimmune hepatitis (AIH). There is scarce information of the role of MAFLD in fibrosis in patients with AIH. This study aimed to describe frequency of steatosis, steatohepatitis and fibrosis in AIH liver biopsies and the impact of steatosis and steatohepatitis on fibrosis severity and survival.

Materials and Methods

Observational, retrospective study of liver biopsies performed prior to initiation of immunosuppressive therapy, between 2014 and 2019. Presence of steatosis, steatohepatitis and fibrosis was recorded. Alcohol and other etiologies of liver disease were excluded. Clinical data was obtained from electronic charts and outcome variables by telephone contact. Chi2 and exact Fisher test and Odds Ratio (OR) were performed (p < 0.05 considered statistically significant).

Results

131 biopsies were analyzed; 76% were female, mean age 56 (15-83) years. Steatosis was present in 27%, steatohepatitis in 14% and advanced fibrosis (≥ F3) in 60%. All patients with steatohepatitis had advanced fibrosis (≥ F3). Presence of steatosis was an independent risk factor for advanced fibrosis (OR 2.97, CI95% 1.22 – 7.21 p = 0.016) and mortality (OR 2.60 (IC95% 1.08 – 6.29), p = 0.033). We performed a sub-analysis including only 66 patients with follow-up were decompensations and hospitalizations were no different between the 2 groups.

Conclusions

In this cohort of autoimmune hepatitis liver biopsies, steatosis and steatohepatitis were risk factors for advanced fibrosis. All patients with steatohepatitis had advanced liver fibrosis and mortality was higher in patients with steatosis. In patients with AIH, MAFLD should be treated to avoid progression to fibrosis.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos